Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of IBI355 in Primary Sjögren's Syndrome
NCT06484855Phase 1Completed
- Sponsor
- Innovent Biologics
- Start
- Jul 2024
- Primary completion
- Jun 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of IBI-355 in primary Sjögren's syndrome (3 arms), sponsored by Innovent Biologics. Primary endpoint: Incidence of adverse events and serious adverse events. Started Jul 2024; status: completed.
02
Drugs
IBI-355
03
Conditions
primary Sjögren's syndrome
Beyond the preview
Go deeper on NCT06484855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06484855.